Buserelin as primary therapy in advanced prostatic carcinoma

Cary A. Presant, Mark S. Soloway, Sol S. Klioze, John W. Kosola, Alun L. Yakabow, Rafael G. Mendez, Peter S. Kennedy, Melody R. Wyres, Virginia L. Naessig, Kimball S. Ford, Charles L. Wiseman, Armand Bouzaglou, Barton Tanenbaum, Daniel Eventov

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


The effectiveness of buserelin, a luteinizing hormone-releasing hormone agonist, was tested in 28 patients with Stages C or D adenocarcinoma of the prostate. Of 24 evaluable patients, there were 13 partial responses (54%) by National Prostatic Cancer Project criteria, median duration greater than 6 months. Nine patients had stable disease (38%), median duration greater than 5 months, and only 2 patients progressed. Performance status improved in 38%, patient-scored pain improved in 46%, and quality of life improved in 57%. Symptoms occurring during treatment consisted of hot flashes, loss of libido, and impotence. A flare of symptoms was observed in only one patient, despite a transient 25% increase in testosterone in 36% of patients. Buserelin is an effective treatment for inducing frequent and meaningful remissions in advanced prostatic cancer.

Original languageEnglish (US)
Pages (from-to)2416-2419
Number of pages4
Issue number10
StatePublished - Nov 15 1985
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Buserelin as primary therapy in advanced prostatic carcinoma'. Together they form a unique fingerprint.

Cite this